Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Market Movers Today: Cloudera Inc (CLDR), Proteostasis Therapeutics Inc (PTI), Tenax Therapeutics Inc (TENX), Lennar Corporation (LEN), and More

Cloudera Inc (NYSE:CLDR) (The Motley Fool)
What happened: Shares of Cloudera (NYSE:CLDR) crashed on Wednesday following the cloud software company’s fourth-quarter report. While Cloudera beat analyst estimates for both revenue and earnings, subpar guidance sent the stock down 39% by 12:30 p.m. EDT. So what: Cloudera posted fourth-quarter revenue of $103.5 million, up 42% year over year and about $4.9 million higher than the average analyst estimate.

Proteostasis Therapeutics Inc (NASDAQ:PTI) (MarketWatch)
Proteostasis Therapeutics Inc. PTI, +6.97% shares rose 12.4% in premarket trade Wednesday after the company’s combination treatment for cystic fibrosis received a “fast track” designation from the Food and Drug Administration. Fast track designation is geared at accelerating the development and review of therapies for serious diseases.

stock, stocks, market, marketing, shares, share, global, chart, bonds, tax, capital, concept, graph, growth, background, rise, statistics, economy, bar, future, loss, business,


Tenax Therapeutics Inc (NASDAQ:TENX) (Benzinga)
Tenax Therapeutics, Inc. shares jumped 64.3 percent to $8.74 after the company reported results of pre-IND meeting with the FDA for Phase 2 study of levosimendan in PH-HFpEF patients.

Lennar Corporation (NYSE:LEN) (CNBC)
Lennar – The home builder reported adjusted quarterly profit of $1.11 per share, well above the consensus estimates of 77 cents a share. Revenue also beat forecasts, with new orders up 30 percent by volume and 38 percent by dollar amount.